Reliability and validity of SF-12v2 among adults with self-reported cancer

Naleen Raj Bhandari; Niranjan Kathe; Corey Hayes; Nalin Payakachat

doi:10.1016/j.sapharm.2018.01.007

Reliability and validity of SF-12v2 among adults with self-reported cancer

Res Social Adm Pharm. 2018 Nov;14(11):1080-1084. doi: 10.1016/j.sapharm.2018.01.007. Epub 2018 Jan 31.

Authors

Naleen Raj Bhandari¹, Niranjan Kathe¹, Corey Hayes², Nalin Payakachat³

Affiliations

¹ Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
³ Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: npayakachat@uams.edu.

Abstract

Background: The SF-12v2 has been validated in general population and other conditions but the evidence is limited in Americans with cancer.

Objective: To assess reliability and validity of SF-12v2 among adults with self-reported cancer using the Medical Expenditure Panel Survey (MEPS).

Methods: Self-reported cancer participants (SCPs) were identified from 2003 MEPS. SF-12v2 was administered as part of self-administered questionnaires. Physical (PCS12) and mental (MCS12) component scores of SF-12v2 were evaluated for reliability (internal consistency, test-retest) and validity (convergent, discriminant, predictive, concurrent).

Results: 420 SCPs were identified with average age of 59.3 years (SE = 0.9). 10.7% had multiple cancers (>1) and 52% had at least one other chronic condition (OCC). Average PCS12 and MCS12 were 45.09 (SE = 0.5) and 50.75 (SE = 0.5). PCS12 and MCS12 demonstrated high internal consistency (α_PCS12 = 0.89; α_MCS12 = 0.88), acceptable test-retest reliability (ICC_PCS12 = 0.82; ICC_MCS12 = 0.73), strongly correlated with most of the expected EQ-5D domains (r = 0.51-0.71), and demonstrated strong convergent validity on perceived health (r = 0.61) and perceived mental health (r = 0.52). PCS12 and MCS12 were able to discriminate between groups with and without physical/cognitive limitations. Only PCS12 was negatively correlated with number of OCCs.

Conclusion: The SF-12v2 is a reliable and valid instrument to quantify health-related quality of life among adults with self-reported cancer.

Keywords: Cancer; Psychometrics; Quality of life; Reliability and validity; SF-12.

Publication types

Validation Study

MeSH terms

Female
Health Status*
Humans
Male
Mental Health
Middle Aged
Neoplasms / pathology
Neoplasms / psychology*
Psychometrics
Quality of Life*
Reproducibility of Results
Self Report
Surveys and Questionnaires*

Grants and funding

T32 DA022981/DA/NIDA NIH HHS/United States